AbbVie Financial Results Overview
AbbVie recently reported impressive financial results for its third quarter, bringing attention to significant achievements in revenue and earnings. The company recorded a diluted EPS of $0.10 on a GAAP basis, which is an 88.6 percent decrease compared to the previous year. However, on an adjusted basis, the diluted EPS was $1.86, marking a decrease of 38.0 percent. These figures incorporate an adverse effect of $1.50 per share due to expenses related to acquired IPR&D and milestone payments.
Noteworthy Financial Metrics
The pharmaceutical giant also reported net revenues of $15.776 billion, representing a 9.1 percent increase year-over-year. On an operational basis, excluding adjustments for currency fluctuations, revenue growth was recorded at 8.4 percent. Within this, the immunology portfolio generated robust sales of $7.885 billion, showing an 11.9 percent increase on a reported basis, boosted by strong performances from Skyrizi and Rinvoq.
Growth Across Various Portfolios
The revenues from AbbVie’s various segments demonstrated growth, especially in the Neuroscience portfolio, which brought in $2.841 billion, an increase of 20.2 percent on a reported basis. Products like Vraylar and Botox Therapeutic contributed significantly, with revenues of $934 million and $985 million, respectively. The company also noted a robust performance in its oncology segment, despite a slight decline, reporting $1.682 billion.
Revenue Performance by Product
Among AbbVie’s notable products, Skyrizi achieved global revenues of $4.708 billion, while Rinvoq contributed $2.184 billion. Humira's revenue, although still significant, fell to $993 million, reflecting a decline as expected due to the increased competition in the market.
Future Outlook and Dividend Increase
AbbVie has raised its adjusted diluted EPS guidance range for 2025, updating it to $10.61 - $10.65, which considers the unfavorable impact mentioned earlier. This move highlights the firm’s confidence in its operational strength and future growth trajectory. Additionally, AbbVie has announced a dividend increase of 5.5 percent, with the new rate beginning with the dividend payable in early 2026.
Investments and Innovations
The company continues to invest in research and development, underscoring its commitment to delivering innovative medicines. Recently, AbbVie gained FDA approval for Rinvoq's expanded use in treating ulcerative colitis and Crohn's disease, marking a significant advancement in its pipeline. Other ongoing projects include trials related to new indications for various therapies and acquisitions aimed at boosting innovative capabilities.
Acquisition Impact
AbbVie finalized its acquisition of Capstan Therapeutics, enhancing its portfolio with a novel treatment for autoimmune conditions through an in vivo targeted platform. This acquisition aligns with AbbVie's strategy to advance its research in biologics and expand its therapeutic offerings.
Shareholder Value and Community Engagement
In addition to strengthening its product line, AbbVie remains dedicated to returning value to shareholders through consistent dividend increases. With a track record of returning significant cash to its investors since its inception, AbbVie sets a standard in the pharmaceutical industry.
Frequently Asked Questions
What were AbbVie's earnings for Q3 2025?
AbbVie reported a diluted EPS of $0.10 on a GAAP basis and $1.86 on an adjusted basis for Q3 2025.
What is the adjusted EPS guidance for 2025?
AbbVie has raised its adjusted diluted EPS guidance for 2025 to a range of $10.61 to $10.65.
How much revenue did AbbVie generate from immunology products?
The immunology portfolio generated revenues of $7.885 billion in Q3 2025.
Is AbbVie increasing its dividends?
Yes, AbbVie announced a dividend increase of 5.5 percent effective February 2026.
What recent awards has AbbVie achieved in the therapeutic areas?
AbbVie received FDA approval for expanding the use of Rinvoq for treating ulcerative colitis and Crohn's disease.
